Primus In News
Indian pharma companies grows footprint in US cancer generics market
16-04-2025
Nilaya Varma, Group CEO & Co-Founder, Primus Partners, highlighted the strong healthcare demand in the US, driven by rising drug prices and a push for affordable care. He emphasized that the Affordable Care Act has boosted access, increasing demand for generics and biosimilars. Additionally, US efforts to diversify supply chains away from China are opening doors for Indian pharmaceutical firms, which are leveraging their generics experience and gaining global approvals through strategic partnerships.
Explore Related Insights
- India’s EV race becomes a three-way battle as Tata Motors, JSW MG Motor India, and M&M lock horns
- Indian online gaming industry with considerable growth potential, regulatory changes cause concerns: Report
- Digital Governance: Changing that Red Carpet into a Green One
- Budget 2026: India to power its clean tech and nuclear ambitions to build an innovation state
